Premium
Biomodulatory metronomic therapy in stage IV melanoma is well‐tolerated and may induce prolonged progression‐free survival, a phase I trial
Author(s) -
Hart C.,
Vogelhuber M.,
Hafner C.,
Landthaler M.,
Berneburg M.,
Haferkamp S.,
Herr W.,
Reichle A.
Publication year - 2016
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.13391
Subject(s) - medicine , tolerability , progression free survival , response evaluation criteria in solid tumors , oncology , cohort , toxicity , phases of clinical research , pharmacology , urology , gastroenterology , chemotherapy , adverse effect
uster RM, Mrowietz U. Successful treatment of severe psoriatic arthritis with infliximab in an 11-year-old child suffering from linear psoriasis along lines of Blaschko. Br J Dermatol 2007; 157: 191–192. 8 Viguier M, Aubin F, Delaporte E et al. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis. Arch Dermatol 2012; 148: 1423–1425. 9 Hyams J, Crandall W, Kugathasan S et al. Induction and maintenance infliximab therapy for treatment of moderate-to-severe crohn’s disease in children. Gastroenterology 2007; 132: 863–873.